Psilocybin: Difference between revisions
From BurnZero
mNo edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
[[File:Psilocybin depression treatment.png|thumb|'''Figure 1'''. Depression symptom reduction from placebo, low dose and therapeutic dose of psilocybin.]] | |||
'''The active [[Psychedelics|psychedelic]] ingredient (when converted to psilocin) found within magic mushrooms'''. Psilocybin has been found to be an effective cure of treatment resistant depression. | '''The active [[Psychedelics|psychedelic]] ingredient (when converted to psilocin) found within magic mushrooms'''. Psilocybin has been found to be an effective cure of treatment resistant depression. | ||
=== Depression Dosage === | === Depression Dosage === | ||
The dose to cure depression has seen a dose dependency 25mg is a better dose than lower doses such 10mg or microdosing<ref>'''Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression'''. Guy M. Goodwin. First published November 3, 2022. N Engl J Med 2022; 387:1637-1648. DOI: 10.1056/NEJMoa2206443. Accessed on 5th November via <nowiki>https://www.nejm.org/doi/full/10.1056/NEJMoa2206443</nowiki></ref>. This equates to 10–20µg l–1 psilocin in plasma, which corresponds to ~60% occupancy of serotonin 2A (5-HT2A) receptors in the neocortex of humans.<ref>'''Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels'''. MK Madsen Neuropsychopharmacology, first published 2019. Accessed on 5th November 2022 via https://www.nature.com/articles/s41386-019-0324-9</ref> | The dose to cure depression has seen a dose dependency 25mg is a better dose than lower doses such 10mg or microdosing<ref>'''Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression'''. Guy M. Goodwin. First published November 3, 2022. N Engl J Med 2022; 387:1637-1648. DOI: 10.1056/NEJMoa2206443. Accessed on 5th November via <nowiki>https://www.nejm.org/doi/full/10.1056/NEJMoa2206443</nowiki></ref>. This equates to 10–20µg l–1 psilocin in plasma, which corresponds to ~60% occupancy of serotonin 2A (5-HT2A) receptors in the neocortex of humans.<ref>'''Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels'''. MK Madsen Neuropsychopharmacology, first published 2019. Accessed on 5th November 2022 via https://www.nature.com/articles/s41386-019-0324-9</ref> | ||
Revision as of 23:02, 5 December 2022
The active psychedelic ingredient (when converted to psilocin) found within magic mushrooms. Psilocybin has been found to be an effective cure of treatment resistant depression.
Depression Dosage
The dose to cure depression has seen a dose dependency 25mg is a better dose than lower doses such 10mg or microdosing[1]. This equates to 10–20µg l–1 psilocin in plasma, which corresponds to ~60% occupancy of serotonin 2A (5-HT2A) receptors in the neocortex of humans.[2]
- ↑ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. Guy M. Goodwin. First published November 3, 2022. N Engl J Med 2022; 387:1637-1648. DOI: 10.1056/NEJMoa2206443. Accessed on 5th November via https://www.nejm.org/doi/full/10.1056/NEJMoa2206443
- ↑ Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. MK Madsen Neuropsychopharmacology, first published 2019. Accessed on 5th November 2022 via https://www.nature.com/articles/s41386-019-0324-9